This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Investors Should Retain Alcon (ALC) Stock For Now
by Zacks Equity Research
Investors are optimistic about Alcon's (ALC) better-than-expected results and robust performance across its popular franchises.
Alcon (ALC) Signs EYSUVIS-Buyout Deal With Kala Pharmaceuticals
by Zacks Equity Research
The acquisition of EYSUVIS complements Alcon's (ALC) Systane family of eye drops offering, strengthening its treatment options for dry eye disease.
Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Grow
by Zacks Equity Research
Alcon (ALC) delivers better-than-expected results in the first quarter, with strong performance across both franchises driving the top line.
Alcon (ALC) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Vision Care with the addition of new products and recent acquisition is likely to have contributed to Alcon's (ALC) first-quarter performance.
3 Medical Product Stocks Set to Beat on Earnings This Season
by Trina Mukherjee
Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how CGC, HAE and ALC are poised ahead of their earnings releases.
What's in the Offing for Synaptics (SYNA) This Earnings Season?
by Zacks Equity Research
Synaptics' (SYNA) third-quarter fiscal 2022 performance is likely to have benefited from increased bookings and new Organic Light Emitting Diode touch-sensor design wins.
EPAM Systems (EPAM) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Though the accelerated digital modernization across industries is likely to aid EPAM Systems' (EPAM) Q1 results, the discontinuation of Russian operations is likely to have hurt the top and bottom lines.
Ball Corp (BLL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Ball Corp's (BLL) Q1 performance is likely to reflect benefits from solid demand for beverage can packaging, can plant capacity expansions and robust aerospace backlog.
fuboTV (FUBO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
fuboTV's (FUBO) first-quarter results are expected to reflect growth in paid subscribers and viewing supported by increased advertiser demand on the company's sports-first live TV streaming platform.
Block (SQ) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Block's (SQ) first-quarter results are expected to reflect strength across its seller base and omnichannel offerings amid rising expenses and the pandemic-led uncertainties.
eBay (EBAY) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
eBay's (EBAY) first-quarter 2022 results are likely to reflect the impacts of strong momentum across Promoted Listings and Managed payments.
Molina Healthcare (MOH) Q1 Earnings Beat on Higher Premiums
by Zacks Equity Research
Molina Healthcare (MOH) boosts premium and bottom-line guidance for 2022, reflecting improving business.
Humana (HUM) Q1 Earnings Beat on Solid Healthcare Services
by Zacks Equity Research
Humana (HUM) still has $2 billion remaining under its share repurchase authorization.
Exact Sciences (EXAS) Q1 Earnings Top Estimates, Sales View Up
by Zacks Equity Research
Robust performances by the Screening and Precision Oncology segments drove Exact Sciences' (EXAS) first-quarter top line.
Charles River (CRL) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Robust global demand for the research model and multiple initiatives to expedite the discovery process are likely to have contributed to Charles River's (CRL) first-quarter results.
Edwards Lifesciences (EW) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Increased adoption of the PASCAL platform along with continued strength in the HemoSphere monitoring platform drove Edwards Lifesciences' (EW) Q1 revenues.
IDEXX (IDXX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in CAG Diagnostics and Water businesses is likely to have contributed to IDEXX's (IDXX) top line in the first quarter.
Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Robust demand in the global dental market with the steady improvement in patient traffic is likely to have contributed to Henry Schein's (HSIC) Q1 performance.
CVS Health (CVS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Increased digital health adoption and growing pharmacy sales are likely to have contributed to CVS Health's (CVS) Q1 performance.
The Zacks Analyst Blog Highlights Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical
by Zacks Equity Research
Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical have been included in this Analyst Blog.
Fulgent Genetics (FLGT) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Strategic investments and expanding operations in China are likely to have contributed to Fulgent Genetics' (FLGT) first-quarter performance.
3 Medical Product Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how ALC, ZBH and CSII are poised ahead of their earnings releases.
LabCorp (LH) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Robust base business growth and notable launches are likely to have contributed to LabCorp's (LH) Q1 performance.
Align Technology (ALGN) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Robust demand for iTero scanners and increasing Invisalign case submissions are expected to have contributed to Align Technology's (ALGN) Q1 performance.
Zacks Industry Outlook Highlights Alcon, STERIS and Abiomed
by Zacks Equity Research
Alcon, STERIS and Abiomed have been highlighted in this Industry Outlook article.